ARTICLE | Company News
PharmAbcine, Triphase deal
November 3, 2014 8:00 AM UTC
PharmAbcine granted Triphase exclusive, worldwide rights, excluding China and Korea, to develop and commercialize TRPH 011. The human bispecific antibody targeting VEGF receptor 2 ( KDR/Flk-1; VEGFR...